Skip to main content
. 2018 Oct 12;33(4):969–980. doi: 10.1038/s41375-018-0276-9

Fig. 1.

Fig. 1

Three-year follow-up of investigator-assessed a progression-free survival and b overall survival. BR bendamustine and rituximab, CI confidence interval, HR hazard ratio, OS overall survival, PFS progression-free survival